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ABSTRACT
Objective: There is an urgent need for safe, effective and acceptable vaginal barrier
methods for the prevention of sexually transmitted diseases (STDs), including HIV. A
variety of existing spermicides have the potential to be used both for prevention of STDs
and unwanted pregnancy. Unfortunately, very little is known about formulation
preferences and the desirable characteristics of vaginal preparations among the diverse
populations of women who would potentially use these products. As product
acceptability ultimately determines compliance and use-effectiveness, such information is
essential to guide the development and formulation of new microbicidal vaginal products.
In this study, we explored vaginal spermicidal preparations containing nonoxynol-9 and
the characteristics that influence user preferences for three formulations. We also studied
the risk of vaginal and cervical irritation associated with low to moderate use of products
containing nonoxynol-9.
Methods: One hundred forty-five sexually active women were enrolled in five sites (Côte
d'Ivoire, Zimbabwe, USA, and Thailand – two sites: one rural, one urban) and asked to
use three different vaginal spermicide preparations containing nonoxynol-9 (a gel, a film,
and a suppository). Each volunteer used each product for four weeks. Structured
interviews and clinical examinations were conducted at biweekly clinic visits. Prior and
to and following product use, women participated in focus group discussions to explore
their knowledge, beliefs, and practices surrounding vaginal product use.
Results: Women enrolled in the New York City site were almost evenly divided in their
preferences of the three formulations; most women enrolled in the Thai sites ranked the
film as their preferred formulation (followed by the gel) due largely to the fact that it was
easy to use, not too messy, and did not produce a lot of discharge; most of the women
enrolled in Zimbabwe also ranked the film as their favorite, followed by the gel, because
it was considered the least messy and provided the least amount of lubrication. In Côte
d'Ivoire, gel was the preferred formulation, followed closely by film. In general, the
suppository was reported to be most messy, with the tendency to melt prior to insertion in
hotter climates. No significant irritation or lesions resulted from product use in any of the
sites. Almost every woman reported that her partner was aware of, and supportive of, her
participation in the study.
Conclusion: The formulation preferences of women should be considered in the
development and introduction of vaginal microbicides: the specific characteristics of
vaginal products and their effect on sexual pleasure and communication will strongly
determine the acceptability – and ultimately the use-effectiveness – of female-controlled
STD-prevention methods.
=
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Introduction
=
There is an urgent need for safe, effective, and acceptable vaginal barrier methods for the
prevention of sexually transmitted diseases (STDs), including HIV. As product
acceptability ultimately determines use-effectiveness, developing and introducing
effective vaginal products for prevention of unwanted pregnancy and/or STD infection
requires insight into users’ perspectives (Elias et al., 1996). Research exploring the
acceptability of woman-controlled barrier methods such as the female condom and the
diaphragm (Do Lago et al., 1995; Gollub et al., 1995) has shown us that adoption of new
methods is often a function of the kind of counseling that women receive with the new
method, as well as having an opportunity to get accustomed to the method. With the
exception of two studies which looked at film, foam, foaming tablets, and suppositories
in four countries in Latin America and East Africa (Steiner et al., 1995; Hira et al., 1995),
little research has explored what constitutes the desirable characteristics of vaginal
preparations among the diverse populations of women who would potentially use these
products. In addition to focusing on the kind of counseling that women receive,
information regarding formulation preferences is essential for guiding the development of
new vaginal preparations, as well as the broader application of existing spermicides.
In this study, we sought to explore the characteristics of existing vaginal products – a gel,
a suppository, and a film – that influence user preferences for various formulations.
Because of the known irritating properties of nonoxynol-9 (Roddy et al., 1993; Kreiss et
al., 1992) we also sought to further knowledge on the risk of irritation to the vagina and
cervix potentially associated with low to moderate use of spermicidal products containing
nonoxynol-9.

Materials and Methods
Study locations/sample
To learn from a range of cultural norms relating to vaginal formulation preferences, we
included a diverse group of study sites. These included the Projet RETRO-CI in Abidjan,
Côte d'Ivoire; Africa; the Siriraj Family Health Research Center in Bangkok, Thailand;
the University of Zimbabwe in Chitungwiza, a township outside of Harare, Zimbabwe;
the University of Khon Kaen in Northeastern Thailand; and the Columbia University
School of Public Health in New York City. A convenience sample of women was
recruited at research centers via fliers and word of mouth or through health care facilities
1
=

=
(e.g., antenatal/MCH clinics in Zimbabwe). To avoid the potential for irritation resulting
from frequent use of nonoxynol-9 containing products, only women whose average coital
frequency was one or fewer acts of intercourse per day were eligible for enrollment.
Except for the Khon Kaen site, which recruited women from a village setting, all of the
participants were drawn from urban populations.
Products used
Study participants used three different vaginal preparations (see Table 1), including the
Vaginal Contraceptive Film® (Apothecus Pharmaceutical Corp., Oyster Bay, NY)
containing 70 milligrams of nonoxynol-9; a vaginal suppository (Ortho Conceptrol®
Vaginal Inserts) with 150 milligrams of nonoxynol-9, and a vaginal gel in a pre-filled
applicator (Ortho Conceptrol® Gel) containing 200 milligrams of nonoxynol-9, both
made by Advanced Care Products (Ortho Pharmaceutical Corp., Raritan, NJ).1
Table 1
Products Used in the Study
Product used

Nonoxynol-9

Apothecus Vaginal Contraceptive Film

70 mg

Ortho Conceptrol Gel

200 mg1

Ortho Conceptrol Vaginal Inserts

150 mg

Study procedure
Women were counseled to use the products together with a male latex condom during
each act of vaginal intercourse. The study employed a crossover design where every
participant used each product for a four-week period, during which time they were asked
to report to the study center every two weeks for an interview and pelvic examination
with speculum for visualization of the cervix and vagina. Women’s experiences with
product use, as well as any evidence of vulvar abnormality, cervical or vaginal discharge,
cervicitis, or mucosal irritation, were coded on the case record forms. Characteristics of
vaginal discharge recorded included color, quantity, odor, and pH. Cervical discharge
============================================
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In our lab we found that only 100-120mg was actually dispensed from the applicator.

=
2

=
was considered abnormal when described as purulent, mucopurulent or bloody. We
defined cervicitis as observation of inflammation of the cervical mucous membrane.
Using standard statistical software (SPSS Version 6.1), we compared symptomatic
reports with clinical signs using X2 tests and Fisher’s exact texts. Significance was
designated as p<0.05. In many cases, however, the numbers were very small and formal
statistical comparisons were not attempted.
Prior to and following product use, all women participated in focus group discussions and
structured interviews to assess their knowledge, practices, and preferences regarding each
vaginal formulation. Women were asked to record each act of intercourse in a coital log
where they also noted whether the study product and/or condoms were used.

Results
Socio-demographic characteristics
The mean age of the 145 women participating in this study ranged from 25 in Abidjan to
37 in Khon Kaen (see Table 2). In the two Thai sites, and in Chitungwiza, nearly all of
the women were married; whereas in Abidjan and New York City married women
constituted only 17 and 42 percent of the sample, respectively. The low figure in Abidjan
Table 2
Selected Characteristics of Study Populations

Age (mean)
Married (%)
Coital frequency in
the month preceding
the study (mean)
Parity (mode)
Ever tried to
convince partner to
use condoms (%)
Always uses
condoms with
partner (%)

=

Abidjan,
Côte
d’Ivoire
n = 31
25
17%
4

Bangkok,
Thailand

Chitungwiza,
Zimbabwe
n = 22
32
96%
18

Khon
Kaen,
Thailand
n = 36
37
100%
5

New York
City,
USA
n = 31
30
42%
8

n = 25
30
100%
5

2
63%

1
40%

4
79%

3
27%

1
97%

0%

0%

9%

0%

55%

3
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may reflect a high prevalence of unofficial—or commonlaw—marriage in Côte d’Ivoire.
The mean coital frequency in the month prior to the study ranged from a low of four in
Abidjan to a high of 18 in Chitungwiza. Parity ranged from one in New York City and
Bangkok to a high of four in Chitungwiza.
Vaginal product and condom use history
There was considerable variation in women’s previous experience with vaginal products,
as reflected in women’s prior use of spermicidal products or vaginal tampons. When
asked why they might use vaginal products in the future, women from the four sites that
reported data for this question stated that the primary reasons would be for protection
from infection alone (40 percent), protection from pregnancy alone (13 percent), or both
(44 percent).2.
A significant proportion of women in New York and the two African sites had tried in the
past to convince their regular partners to use condoms (see Table 2). Consistent condom
use, however, was reported by only 55 percent of women in New York City, nine percent
in Chitungwiza, and no women in Abidjan, Bangkok, or Khon Kaen.3 Many women
reported that their partners refused to use condoms because they did not want to
contracept. During the study, the percentage of women whose partners used condoms
during use of the study product was low, and was about the same regardless of which
product the woman was using (26, 29, and 30 percent, respectively, for film, gel and
suppository).
Partner’s knowledge of product use
When asked whether they were able to use the study products without their partner’s
knowledge, most women in this study reported that they preferred to inform their partners
that they were using vaginal products—both in the context of the study, and in a
hypothetical, future framework (see Table 3). Only roughly one-quarter of the women
chose not to inform their partners, with even lower percentages in the Thai sites. Most
women preferred telling their partners at the outset of the study, in case they or their
============================================
2

The Khon Kaen site did not report data for this question and 3% of participants at the other four sites were
“not sure” or had missing data for this question.=
3
New York site investigators felt that, given the probability that participants volunteering for this study are
particularly interested in barrier prevention methods, the consistent condom use levels reported for New York
may actually be substantially higher than in the general population.=
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Table 3
Able to Use Product Without Partner’s Knowledge
Abidjan, Côte
d’Ivoire
n = 31

Bangkok,
Thailand
n = 25

Chitungwiza,
Zimbabwe
n = 22

Khon Kaen,
Thailand
n = 36

New York
City, USA
n= 31

Film

40%

0%

20%

3%

15%

Gel

25%

4%

17%

14%

27%

Suppository

20%

0%

14%

4%

26%

partners subsequently experienced problems with a particular product. In Chitungwiza
women were particularly concerned about having to explain the presence of a product if
her partner detected it. Others said that their partners supported them in using vaginal
products, especially if vaginal product use was perceived to enhance sexual frequency or
pleasure. There was no correlation between formulation preferences and the desire to
hide product use from one’s partner.
Experience with study products
In most cases, women found the suppository to be the messiest and, therefore, least
desirable of the formulations: it tended to melt at the tropical ambient temperatures of
several of the study sites and, consequently, needed refrigeration in order to prevent
melting prior to insertion (see Table 4).

Table 4
Women's Preferences for Products, by Site
Abidjan, Côte
d’Ivoire
n = 31
Product liked
gel
most
Product liked suppository
least

Bangkok,
Thailand
n = 25
film

Chitungwiza,
Zimbabwe
n = 22
film

Khon Kaen,
Thailand
n = 36
film

New York
City, USA
n = 31
gel

All sites
film

suppository

gel

suppository

film

suppository

As with the earlier three-country study (Steiner et al., 1995), film was the overall
preferred formulation in three of the five sites in that it was considered to be the most
=
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"natural" and was liked by many of the women’s partners. Women in Khon Kaen,
Bangkok, Chitungwiza, and Abidjan all stated that they liked the film especially, due to
the fact that it left the vagina feeling “tight” or “fit.” Indeed, preferences were often
related to perceptions of “wet” versus “dry” (see Table 5). Due to the fact that the film
has a tendency to stick to damp fingers, however, it was considered the most difficult to
insert by many users. For those women who experienced initial difficulty in inserting the
film, however, their confidence and ability to use this product increased substantially with
experience and supportive counseling.
The most preferred formulation in New York and Abidjan, the gel was generally deemed
the easiest to apply and had an advantage of not requiring a waiting time following
Table 5
Selected Product Characteristics Described by Study Participants

Film

Gel with
applicator

Suppository

Advantages
Least messy
Easy to conceal/dispose of
Can’t feel it when it’s in
Enhanced sexual pleasure
No waiting time before product is
effective
Applicator precludes need to touch
oneself directly
Enhanced sexual pleasure
Lubricating
Small, easy to conceal/dispose of

Disadvantages
Tends to stick to fingers during
application
Long wait for it to melt prior to
intercourse
Often runny
Applicator painful to use
Applicator difficult to conceal/
dispose of
Tendency to melt at warm ambient
temperatures
Creates a lot of messy discharge

insertion. It was also preferred by older women in the Khon Kaen site specifically
because of its lubricant qualities. Many other women, however, complained of excessive
lubrication and “runniness” following intercourse with the gel product.
We found that preferences after actual use did not correlate well with those expressed in
hypothetical pre-use focus group discussions, especially in those sites where women had
little prior experience with vaginal product use. For example, some participants were
“intrigued” by unfamiliar products and predicted that they would like them best (e.g.,
=
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women in New York thought the film was wonderfully small, and women in Bangkok
were quite taken with the gel’s applicator). On the other hand, women’s hypothetical
preferences were often informed by what they were already familiar with. For example,
in Khon Kaen women thought that they would like the suppository because they were
familiar with the use of suppositories for the treatment of vaginal yeast infections whereas
they had never seen a vaginal film or applicator before. Following actual product use,
however, the characteristics that women often found interesting, familiar or appealing no
longer mattered in their overall ranking of the product.
In discussions both before and after product use, women felt strongly that vaginal
products should be formulated so as to not interfere with sexual pleasure. In fact, in three
of the sites (Abidjan, Chitungwiza, and Khon Kaen), women favored some products
because they enhanced sexual pleasure. In general, reports of the partners’ and women’s
reactions to the different products reinforced each other.
Disposal was a major concern in Zimbabwe where women reported burning the used
applicators and packaging to avoid having neighbors and/or children find evidence of
their use. Similarly, participants in Khon Kaen expressed concern about their need to
keep the suppositories in the refrigerator where other family members could see them.
There were often trade-offs regarding product characteristics. For example, some women
liked the ease of insertion of the gel, but also felt it was too messy. Several of these
women compensated for this by decreasing the volume of gel they applied. Some women
reported that use of certain products resulted in increased frequency of intercourse.
However, overall product preference was not a function of coital frequency. Of interest,
women in some sites either perceived that the products had medicinal or hygienic effects
(Chitungwiza) or reported an improvement in chronic genital symptoms, such as pruritus,
after product use (Khon Kaen). Despite specific drawbacks to each formulation, study
participants expressed great interest in the products, and many stated that they would
continue to use any of them – even their least preferred formulations – if they were
available and approved for STD prevention.
There was considerable variation between sites in regard to reports of “some,”
“moderate,” and “high” levels of discomfort or irritation due to product use (see Table 6).
Women in most sites reported the least discomfort in using the film, and the most in gel
use.

=
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Table 6
Reported Discomfort or Irritation with Product Use

Film
Gel
Suppository

Abidjan,
Côte
d’Ivoire
n = 31
4%
0%
5%

Bangkok,
Thailand

Chitungwiza,
Zimbabwe

n = 25
0%
21%
21%

n = 22
5%
11%
5%

Khon Kaen,
Thailand
n = 36
3%
36%
15%

New York
City, USA

All sites
n = 145

n = 31
7%
19%
11%

4%
20%
12%

Analysis of clinical observations, however, indicates that irritation of the cervix or vagina
was fairly uncommon (see Table 7). Among women’s reports of symptoms and clinical
findings for each product use group, there was no association between clinical irritation
and reported symptoms (Fisher’s exact test for intervals of gel use (p=1.00), for intervals
of film use (p=0.43), or for intervals of suppository use (p=0.07)). Despite differences in
partners’ preferences, which were reflected in women’s own stated preferences, reported
partner irritation was fairly low across the products (six, eleven, and nine percent of male
partners reported irritation with film, gel, and suppository, respectively).
Table 7
Number of Clinical Signs Observed/Total Number of Clinical Visits
Vulvar
Vaginal
abnormality discharge
Baselinea
3/145
4/145
Film
3/290
3/290
Gel
1/290
5/290
Suppository
2/290
0/290
a

Cervical
dischargeb
4/145
11/290
9/290
8/290

Cervicitis
0/145
1/290
1/290
0/290

Pain on bi-weekly
manual exam
3/145
1/290
0/290
0/290

Total
14/145
19/290
16/290
10/290

Clinical observations at enrollment.
Included cervical discharge described as “purulent,” “mucopurulent,” and “bloody.”

b

=
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Discussion
Overall, we observed considerable variation in users’ perspectives and formulation
preferences both within and between sites. As with the earlier three-country study
(Steiner et al., 1995), film was the overall preferred formulation. Nevertheless, cultural
norms affected specific preferences for relative “dryness” of the formulations, and
generational differences, even within the same site, influenced the degree of lubrication
considered desirable. This suggests that, in the development of new vaginal
microbicides, multiple products will be required to meet the needs of all users.
Because of the wide range of cultural norms governing desirable fertility levels, and given
women’s differing personal expectations and needs, study participants expressed
considerable interest in the possibility of using a vaginal microbicide that would be nonspermicidal. Although it could be argued that most women, at any given point in their
lives, probably do not want to become pregnant, it can also be noted that nearly every
woman, at some point in her life, does want to conceive – preferably without putting
herself at risk of infection. Ideally, both contraceptive and non-contraceptive products
should be pursued in research and development efforts.
Storage, application and disposal issues must be taken into consideration as well. With
regard to packaging, many study participants commented favorably on the ease with
which they were able to conceal the film, both in storage and in disposal. It will be
important to consider the amount of excess “packaging” that characterizes a given
product. In almost every site, at least some of the women reported that they and their
partner enjoyed using the products because their use was seen as sexy: for those women,
a product that is perceived as enhancing sexual pleasure is more likely to be used. In a
few sites, women felt that the products “cured” them of various vaginal complaints –
even though they were told what the products were for. Clearly, the “trade-offs” between
promoting a product for disease prevention versus increasing sexual pleasure or vaginal
health must be further explored.
As noted above, and as has been observed in other low-frequency studies of nonoxynol-9
use (Feldblum, 1996), the numbers of women reporting any kind of discomfort were very
low, as were the number of women with clinical signs of irritation. Although women
were encouraged to come in to the clinic at any time they experienced discomfort with
any of the products, we observed that women only came in for their scheduled two-week
visits. We must therefore be cautious in drawing conclusions about a lack of correlation
=
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between clinical signs and symptoms, given that women may indeed have had clinical
signs of irritation at the time they were experiencing symptoms that had cleared up by the
time they came in for their examination. Such a lack of correlation in lower frequency
use of nonoxynol-9 was also observed in a previous study (Roddy et al., 1993).
Women in this study, many of whom were family planning clients or hospital employees,
expressed little interest in covert methods. In fact, many of the participants stated that
they “wouldn’t dream” of hiding product use from their partner. Women in partnerships
characterized by higher levels of violence, coercion, or commerce, however, might have a
greater need for products that could be used without a partner's knowledge. It is also
possible that covert use would be more common outside the context of a research study.
Despite the fact that products such as those employed in the study have been available in
several of the study sites as over-the-counter spermicides for many years, the frequent
clinic visits and intense clinical observations of this study gave some participants the
impression of “experimental” product use. A few women mentioned in the focus group
discussions that their partners expressed some concern about the nature of such
experimentation. The study may have thus introduced a concern for gaining partner
consent that may not exist when products are commercially available.
For this group of women, partner’s perceptions of product characteristics and the
dynamics of partner communication proved to be very important. It is therefore critical to
explore men’s attitudes and beliefs regarding vaginal microbicide use more explicitly in
future studies.
A greater understanding of users” perspectives and preferences will help in the preclinical
development of new vaginal products: information on how, why and whether women
will use new products is essential to help us to create a product that will actually be
accepted and used. Yet, as evident in other studies (Do Lago, 1995; Gollub, 1995), there
is also a need to consider the counseling and information needs of potential users and the
important role of service providers. Ultimately, changing the products may only be one
half of the equation: we must also learn more about the best ways to introduce and
support products within service delivery programs.
Given the trade-offs that women and their partners face in using vaginal products, we
must also learn more about the dynamics of actual product use. Few people will adhere
strictly to package instructions, especially when using products outside the context of a
clinical study. For instance, if women are going to decrease the volume of vaginal
applications because the product is otherwise too messy, we must know this in order to
=

10

=
ensure that dosage is adequate under real use conditions. As with other user-controlled
methods, product acceptability is a central determinant of use-effectiveness. Ultimately,
the development and introduction of any new vaginal microbicide will need to take into
careful consideration the kinds of findings of this and similar studies, in order to ensure
that women are armed with the best information and products available to protect
themselves from infection.
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